Stephens analyst Sudan Loganathan initiated coverage of Actinium Pharmaceuticals with an Overweight rating and $25 price target. Actinium’s long-standing focus on radiopharmaceuticals is “nearing a milestone,” namely the BLA/MAA regulatory filing for Iomab-B in for unfit relapsed or refractory acute myeloid leukemia, or AML, the analyst tells investors. The firm anticipates a successful filing and regulatory approval that leads to the company’s first commercial launch in 2025, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATNM:
- H.C. Wainwright sees Actinium as buyout candidate after Mariana deal
- Actinium Pharmaceuticals’ Iomab-B improves survival in refractory AML
- Actinium Pharmaceuticals reports Iomab-B Phase 3 SIERRA trial results
- Actinium Pharmaceuticals’ Iomab-ACT included in CAR T-Cell therapy study
- Biotech Alert: Searches spiking for these stocks today